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Abstract: Background: Enteroviruses are a group of common non-enveloped RNA viruses that cause
symptoms ranging from mild respiratory infections to paralysis. Due to the abundance of enterovirus
infections it is hard to distinguish between on-going and previous infections using immunological
assays unless the IgM fraction is studied. Methods: In this study we show using Indirect ELISA and
capture IgM ELISA that an IgG antibody response against the nonstructural enteroviral proteins 2A
and 3C can be used to distinguish between IgM positive (n = 22) and IgM negative (n = 20) human
patients with 83% accuracy and a diagnostic odds ratio of 30. Using a mouse model, we establish
that the antibody response to the proteases is short-lived compared to the antibody response to the
structural proteins in. As such, the protease antibody response serves as a potential marker for an
acute infection. Conclusions: Antibody responses against enterovirus proteases are shorter-lived
than against structural proteins and can dierentiate between IgM positive and negative patients,
and therefore they are a potential marker for acute infections.
Keywords: enterovirus; acute infections; proteases
1. Introduction
Enteroviruses are non-enveloped positive stranded RNA-viruses (Group IV viruses) that cause a
wide variety of diseases ranging from mild respiratory infections to severe conditions such myocarditis,
meningitis, encephalitis, flaccid paralysis, and systemic “septic” infections in young infants [1].
In addition to acute infections, enteroviruses have been linked to the development of chronic diseases
such as cardiomyopathies, asthma, and autoimmune diseases including type 1 diabetes where persistent
viral infections may also be involved [2–6]. Enteroviruses (mainly EV-71 and CAV16) are also the main
causative agents of hand-foot-and-mouth disease [7]. Enterovirus infections are frequent in all age
groups causing significant morbidity particularly in young children and are a heavy health-economic
burden on society [8].
Reliable diagnosis of enterovirus infections is a prerequisite for oering patients eective treatment
and for the avoidance of unnecessary antibiotic prescriptions. There are no licensed antivirals available
but some drugs including Pleconaril and immunoglobulins have been trialed in the treatment of
severe infections [1]. The lack of, or wrong diagnosis of infections often results in the misdiagnosis
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of enterovirus infections as bacterial infections and subsequent treatment with antibiotics [9,10],
which underscores the need for tests that can specifically detect acute enterovirus infections. Enterovirus
infections are currently diagnosed mainly by the detection of viral RNA in clinical specimens using
RT-PCR. This method is highly sensitive and specific but requires specialized laboratories and
sophisticated equipment. Another limitation with applying RT-PCR-based diagnostics on blood
samples is that viremia is short-lived, and viruses can only be detected for a few days [11]. Serological
methods can overcome this problem since antibody responses last longer and said assays also require
less sophisticated laboratory facilities. Enterovirus infections can be diagnosed by either detecting
enterovirus specific IgM class antibodies in acute-phase samples or through demonstrating significant
increases in IgG antibody titers in paired sera. Both of these assays have been used in clinical diagnostics,
but their wider use has been curbed by limited sensitivity in their ability to detect antibodies induced
by over one hundred enterovirus types and, in the case of IgG assays, the need for paired sera which
is a challenge for use in the clinical diagnostics of infections. Thus, there is a clear need for better
serological assays to improve the clinical diagnostics of enterovirus infections.
The enterovirus genome is expressed as a single polyprotein that is cleaved into structural (capsid)
and non-structural proteins, such as the proteases. Non-structural proteins are not included in the
virion and only appear when the RNA-genome is translated in the host cell. The non-structural
proteins carry out multiple functions that aid with viral replication and immune response evasion
strategies during infection [12]. The enterovirus proteases 2A and 3C are essential non-structural
protein components in the life cycle of a virus as they are responsible for cleaving the virus polyprotein
into its subunits.
Historically, serological assays have used structural capsid proteins or purified whole viruses
as antigens, while antibody responses against non-structural proteins are less well characterized.
However, antibody responses to non-structural proteins can oer advantages in clinical diagnostics.
First, these proteins are more conserved among dierent enteroviruses than the structural proteins [13],
providing an option to detect antibodies against several dierent enterovirus types. Second, since
non-structural proteins are only produced during an active virus infection, antibodies against them
could be used to distinguish vaccine-induced antibodies from those that have been induced by natural
infections. This would be advantageous when analyzing the ecacy of inactivated enterovirus vaccines.
In fact, antibodies against non-structural proteins, such as 2C and 3ABC have been routinely used
for screening livestock to distinguish between foot and mouth disease (FMD) infected and FMD
vaccinated animals [14,15]. Antibodies against non-structural enterovirus proteins have also been
found in humans during acute EV-71 and CAV16 infections, especially against 3A, 3C and 3D [7,16].
The diering IgG antibody responses towards structural and non-structural proteins have been used to
dierentiate acute and chronic hepatitis C virus infections (another Group IV virus) [17], and varying
antibody response profiles have also been connected to the severity of enterovirus 71 infections [7].
In the present work, our aim was to study the nature of IgG antibody responses against the
non-structural enteroviral proteins 2A and 3C and to compare these responses to those raised to the
enteroviral structural capsid proteins. We set out to study these responses in human patients with
IgM-confirmed acute enterovirus infections and in control subjects, as well as in enterovirus-infected
mice. The results suggest that the analysis of antibodies against viral proteases provides information
that helps to diagnose acute enterovirus infections.
2. Materials and Methods
2.1. Animal Husbandry and Ethics Statement
C57BL/6J mice were housed in isolator cages under SPF conditions at the Karolinska University
Hospital Huddinge, Stockholm, Sweden. Infections were performed according to local and national
regulations, and the study was approved by the Stockholm South Animal Ethics Board (Södra
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Djurförsöksetiska nämnd; Number: S46-14; Approval date: August 29th 2014, 5-year approval,
the animal work with subsequent analyses were performed within this period).
Animals were infected with Coxsackievirus B3 (CVB3) or mock-infected with PBS. Blood and
tissue samples were collected at dierent times for histological analysis and ELISA (See Appendix A
for details).
2.2. Human Samples Ethics Statement
Enterovirus IgM positive serum samples were originally tested in the virus diagnostic laboratory
in Turku University Hospital for the diagnosis of patients’ acute enterovirus infections. The samples
were anonymised and used in the development of antibody tests. Control serum samples included
laboratory personnel and the participants of the Autoimmune defence and living environment-study
(ADELE) [18] and negative control samples from 6-month old children who were participating in the
Diabetes prediction and prevention-study (DIPP) [19]. All participants or their legal guardians gave
informed consent.
2.3. Preparation of ELISA Antigens
The VP1 antigen (CVB3, strain Nancy, original sequence from GenBank: M33854.1) were prepared
as described in [20]. The production of recombinant proteases 3C and 2A (CVB3, strain Nancy, original
sequence from GenBank: M33854.1) was carried out as in [21]. CVB3 was grown in green monkey
kidney cells (Vero) as described previously [6,22]. The adenovirus and parainfluenzavirus antigens
were obtained from Heikki Hyöty’s laboratory. See Appendix A for details on antigen preparation.
2.4. Protease ELISA
Conditions for protease ELISA were optimized using pooled mouse sera and Nanogam® before
running individual mouse and human samples. Samples were run with a typical indirect ELISA
protocol. See Appendix A for details on antigen preparation.
2.5. Capture IgM-ELISA for Human Samples
Enterovirus IgM antibodies were analyzed by a standard method used in clinical virus diagnostic
laboratory in the Turku University Hospital, as described by [23]. See Appendix A for details on
antigen preparation.
2.6. Data Processing
The ELISA results from mice were analyzed in individual animals: The average signal for each
antigen and dilution were divided by the same mouse’s corresponding pre-infection response to obtain
a fold change in signal intensity. Average signal + 3 times standard deviation from parallel serum free
wells for each antigen was subtracted from the raw data. The fold changes were then compared to the
mock-infected controls using one-tailed Mann–Whitney’s rank test at dierent time points utilizing
GraphPad Prism v.5.02.
The human data processing was done dierently as there were no paired samples in the acute
versus control dataset: Absorbance data (with serum free control signals subtracted) from the assay
was used to compare the two groups. Wilcoxon signed-ran test was used for comparing groups.
Data processing for the human samples was done using R version 3.4.4 with the following packages:
ggplot2, ggpubr, GGAlly, ggExtra, reshape, cowplot, and tidyverse. Final layouts for figures were done
using Inkscape version 0.92.3.
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3. Results
3.1. Enterovirus Proteases Are Expressed in Mice Shortly after CVB3 Infection
In a previous study, we found that monoclonal antibodies can detect 2A and 3C in infected mouse
tissue [21]. Here we found that these antibodies detected viral proteases in tissue samples taken early
after infection, but not in samples collected at later time points (Figure 1). Pancreata from CVB3
infected mice collected 3 days post infection (dpi) showed positivity in the exocrine pancreas with both
3C and VP1 (1), while the staining was absent at time points after 7 dpi (Table S1).
3C
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Figure 1. Viral 3C and VP1 proteins are expressed in murine pancreata following infection with
Coxsackievirus B3 (CVB)3. C57BL/6J mice were mock-infected with PBS (A,C,E,G) or infected with
CVB3 (102 PFU/mouse) (B,D,F,H) for 3 days. Pancreas sections were stained with either an antibody
detecting 3C (A,B) or a directly biotinylated antibody detecting VP1 (E,F). As control for the 3C staining,
sections from mock-infected and CVB3 infected animals were stained with a biotinylated secondary
antibody alone (C,D) prior to visualization of antibody binding by DAB as described in Materials and
Methods section. For the VP1 controls, sections were incubated without secondary antibody prior
to visualization of antibody binding (G,H). Representative sections are shown (n = 3–4 animals per
condition). Positivity is indicated with the brown staining. Original magnification 10.
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3.2. Pooled Mouse and Human Sera Contain Antibodies against Enteroviral Proteases
In order to compare the profiles of the antibody responses against viral proteases to those
against viral capsid proteins, VP1 and heat inactivated whole virions were used as antigens. Initially,
we examined for the presence of 2A, 3C, VP1, or CVB3 antibodies in pooled human sera from
(presumably naïve) 6-month old children, in a concentrated pool of adult human IgG (Nanogam®),
and also in pooled sera from naïve or enterovirus infected mice (21 dpi) using ELISA (Figure 2).
We saw that there was a strong antibody reactivity towards the proteases present in the Nanogam®
preparation, which was comparable to the antibody reactivity to structural proteins (Figure 2A).
In comparison, pooled sera from six-month old children showed lower reactivity to the proteases
(Figure 2A). Enterovirus (CVB3) infected mice also developed an antibody reactivity against viral
proteases, which is lower in uninfected mice, yet, the antibody reactivity to the viral proteases was
weaker than the response to the structural VP1 protein and the whole virus (Figure 2B). These results
confirm that we can detect antibodies against the proteases in murine sera using ELISA which
corresponded with protease expression in the pancreas by immunohistochemical analysis using
protease-specific monoclonal antibodies.
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3.3. Time Dependent Antibody Response against Enteroviral Proteases and Structural Proteins Dier in Mice
To better understand the kinetics of the antibody responses during an infection we decided to
examine this in the controlled setting of a murine enterovirus infection model. Mice were infected with
the enterovirus (CVB3) or mock infected with PBS. Blood samples were collected with 7-day intervals
after the infection and analyzed for dierent enterovirus antibodies by ELISA.
Dierences between the antibody response towards the proteases and the structural proteins were
detected (Figure 3). In enterovirus-infected mice, protease specific antibodies peaked at 7 dpi and
declined to levels close to those seen prior to infection by 21 dpi (Figure 3A,B). The antibody responses
against proteases only diered significantly (p < 0.05) from the control mice at 7 dpi. In comparison,
the antibody response against the structural proteins and whole virus continued to increase until 14 dpi
and remained significantly higher (p < 0.05) at this time point in CVB3 infected mice than in control
mice (Figure 3C,D). Statistics for 21 dpi could not be calculated because some mice were euthanized
prior to this time point leading to insucient sample numbers. These results examining the duration
of enterovirus antibody responses over time in mice suggest that upon infection, the protease antibody
response is weaker and shorter in duration than the responses against the enterovirus structural
proteins (See Table S2 for interassay variabilities for mice ELISA data).
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Figure 3. CVB-infection induces a short-lived antibody response towards CVB3 proteases in mice.
Antibody responses towards the protease antigens (A) 2A and (B) 3C (at 1:1000 dilutions) and to the
(C) structural proteins in whole virus and (D) the capsid protein VP1 (1: 64,000) in CVB3 infected
mice measured using ELISA. The data is shown as the fold change compared to antibody responses
from pre-infection serum samples. Each data point is an average of three parallel samples. Stat:
Mann–Whitney test, means and standard errors of means shown as gray bars, * p < 0.05 and ** p < 0.001.
3.4. Antibody Responses towards Viral Proteases during Acute Enterovirus Infection in Humans
Antibodies against the enteroviral proteases were analyzed in human serum samples which had
been tested for IgM antibodies against enterovirus structural proteins. Samples taken from patients
with an acute enterovirus-infection (IgM positive, n = 22) were used as well as randomly selected control
subjects (IgM negative, n = 20). Sera from IgM positive, acutely infected patients had significantly
higher reactivity for the 2A (p = 1.5  10 3) and 3C (p = 1.3  10 4) proteases when compared to healthy,
IgM negative controls, while antibodies against structural proteins (whole virus particle and the VP1
protein) did not dier between the groups (Figure 4A). In addition, the parainfluenza and adenovirus
antibody levels showed no dierence between the two groups (Figure 4A).
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Next, we studied whether there was any correlation between the antibody reactivity against
dierent virus antigens. The responses to the 2A and 3C proteins had a moderate correlation (Spearman
correlation (Cor) = 0.55) being higher than for any of the other antigen pairs, apart from whole virus
and VP1, which expectedly had a strong correlation (Cor = 0.91) (Figure 3). Most importantly, only the
Viruses 2020, 12, 78 8 of 15
responses against 2A and 3C show potential for distinguishing between the IgM positive and negative
patient groups (Figure 4A) (See Table S3 for interassay variabilities for human ELISA data).
3.5. Sensitivity and Specificity of Detection of IgG against Viral Proteases in the Diagnosis of IgM-Positive
Acute Enterovirus Infections
Detection of IgM enterovirus antibodies has been used in the diagnosis of acute or recent
enterovirus infections. We decided to study if it is possible to define criteria for detecting acute
IgM positive infections in humans based on the detection of IgG class antibodies against enterovirus
proteases. As a baseline, we chose to look how the test performed when using criteria based on
the 20 presumably naive serum samples from 6-month old children (cuto set at average signal +
3standard deviation) (marked with red in Figure 5A). These cutos (0.46 and 0.25 for 2A and 3C
respectively), while highly specific, gave poor sensitivity (62%) and overall accuracy (69%) due to high
number of false positives for the adult data (Figure 5B). Thus, we chose to adjust the criteria based on
the IgM ELISA-data. By comparing the 2A and 3C protease antibody reactivities in sera from patients
with acute enterovirus infections with sera from healthy controls by IgM-ELISA (Figure 4), we decided
upon suitable criteria for the recognition of acute enterovirus infections. We simulated diagnostic
cuto values based on visual inspection for the antibody responses to both proteases and interpreted
the data so that if a patient had a 2A signal higher than 0.55 or 3C signal higher than 0.5, the patient
was considered acutely infected. Visualization of the dataset is shown in Figure 4 A along with the test
descriptors (Figure 5B,C).
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Figure 5. Acute enterovirus infection criteria and test descriptors based on ELISA results. (A) Dierent
cuto criteria based on 2A and 3C signals (based on 6-month children average + 3  SD (n = 20) or the
adjusted thresholds) and IgM positivity. In the plot (A), IgM positive data points are colored red and
control data points are cyan. (B) Confusion matrix and test descriptors calculated from the traditional
cuto values based on results from 6-month children comparing the new protease-ELISA test to the IgM
ELISA by analysis in R. Sensitivity is the proportion of true positives and specificity is the proportion
of true negatives correctly categorized with respect to IgM ELISA by the protease ELISA. LR+ and LR–
stand for positive and negative likelihood ratios respectively and DOR the overall diagnostic odds
ratio. (C) Confusion matrix and test descriptors based on the adjusted diagnosis criteria.
Based on the adjusted cutos, the protease-ELISA results are highly comparable to the IgM-ELISA
results with high accuracy (83%), specificity (75%), and sensitivity (91%) between the two methods.
As such, the protease antibody ELISA assays provide a valid and easy method to detect acute enterovirus
infections in patient sera.
4. Discussi n
While antibody responses against enterovirus capsid proteins have been studied widely and used
in research and diagnostics, the responses that target viral non-structural proteins, and specifically
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the proteases, are poorly characterized in humans. The present study shows, for the first time, that
both mice and humans produce robust antibody responses against enterovirus proteases 2A and 3C,
and that these responses are associated with acute or recent enterovirus infections. This suggests that
detection of antibodies against enterovirus proteases could be used as a biomarker of recent infection.
So far, rapid serological diagnosis of acute or recent enterovirus infection has relied on the
detection of IgM class antibodies in a single sample. However, the performance of IgM assays can
vary considerably depending on several factors. The most important limitation is the occurrence of
false negative IgM results due to the lack of clear IgM response in some enterovirus infections [24]
or the high number of serotypes (>100) which are dicult to completely cover in a single assay [23].
For example, the IgM assay in this study detected VP1 proteins from EV-A and EV-B enteroviruses and
we found that there is a fraction of patients that are IgM negative but have high responses towards
the 2A protease. This indicates that those patients may have been missed in the IgM assay due to
lack in the sensitivity of the assay. Thus, there is a clear need for improved rapid serological assays
to detect acute and recent infections. The results of the present study suggest that detection of IgG
class antibodies against viral proteases oers a feasible way to develop new serological assays for this
purpose. Protease antibodies peaked and levelled o rapidly after acute phase infection in mice and
were also at higher levels in IgM positive human specimens. Interestingly, the use of antibodies against
either of the two proteases as an indicator of acute infection in these human samples reached 91%
sensitivity and 75% specificity when compared to detection of IgM. However, the aim of the present
study was not to validate the use of protease antibodies in enterovirus diagnostics and further work is
required to develop such test.
To assess the diagnostic value of the proteases as acute infection markers, it would be important
to study the antibodies’ cross-reactivities with other enterovirus proteases. Larger sample set from
infected humans should be studied and the relationship between IgM and IgG responses towards the
proteases should be examined further. Zhang and collaborators [7] mapped the IgG and IgM antibody
responses of EV71-infected human sera to the linear epitopes of the EV71 polyprotein. Patients, who
did not produce IgG antibodies towards a group of viral antigens, including 3C, had a more severe
infection than the other two groups [7]. In the current study we observed that the correlation between
2A and 3C antibody reactivity was not very high (Cor = 0.55; Figure 4B), indicating that during an
acute infection some people raise a higher level of antibodies against one virus protease compared to
the other. However, due to the limited number of samples and the information available regarding the
patients used in this study, it is hard to draw any comprehensive conclusions, and therefore it would
be intriguing to compare the proteases and VP1 IgM antibody responses in a larger sample set. If in a
similar manner to the case of EV71 [7], there is a correlation between disease outcome and dierences
in the immune responses to 3C and other antigens such as 2A, testing for individual protease responses
could give valuable information about the severity of the infection.
A recent study used VirScan [25] technology to locate the immunodominant epitopes (against
which antibodies were found in >50% of seropositive cases) for the antibodies against the 44 most
common viruses that 78 newborn children were seropositive for [26]. This is a reasonably accurate
representation of the mother’s IgG fraction, as under normal circumstances, IgM antibodies are
generally unable to penetrate the placenta. Viruses in that study included the enteroviruses A, B,
and C, as well as rhinoviruses A and B. The immunodominant epitopes for these viruses in the IgG
class antibodies were mainly directed against the VP4 and VP1 structural proteins, of which the latter
contains the enterovirus and rhinovirus group specific (broad-reactive) epitopes [27,28]. Additionally,
antibodies against the 3A non-structural protein were observed among the most common antibodies
in their study, indicating that the response against 3A was long-lived [26]. In contrast, IgG antibody
responses against 2A and 3C, which do not contain the immunodominant epitopes, could provide a
better metric for distinguishing acute infection than antibodies against the structural proteins or 3A.
In addition to the routine diagnostic applications, the detection of antibody responses against
enterovirus proteases could oer new opportunities for the evaluation of vaccine ecacy in preclinical
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and clinical studies. This topic is very timely since new kinds of inactivated poliovirus vaccines are
being developed for the end-game of poliovirus eradication and vaccines against other enteroviruses
are also in clinical development; e.g., enterovirus 71 vaccines have already been licensed in China
and a Coxsackie B virus vaccine is approaching clinical trials [29]. These vaccines are based on highly
purified viruses that have been inactivated with formalin and do not contain non-structural proteins.
Thus, detection of antibody responses against viral proteases would make it possible to distinguish
between responses that have been mounted to the vaccine from those mounted during acute enterovirus
infections, oering an option to study vaccine-induced protection against natural infections in a similar
manner to the livestock industry where the non-structural proteins 2C and 3ABC have been used to
distinguish between immune responses to HFMD infections and HFMD vaccines [15].
The present study has certain limitations. The protease antigens used to detect the IgG responses
represented only one enterovirus serotype and screening of antibody response towards proteases from
other serotypes was not done. Thus, it is possible that responses against these proteins could dier
between infections caused by dierent serotypes. However, since the proteases are more conserved
between dierent enterovirus serotypes [12] than the VP1 proteins, we expect that such cross-reactivity
would occur. Moreover, high protease antibody levels were found in IgM positive human subjects,
whose acute infections were most likely caused by a wide range of dierent enteroviruses (samples
were collected during 2016–2019). It is possible that this kind of cross-reactivity could help to cover a
wide range of dierent enteroviruses in one assay, and it should be evaluated in further studies.
5. Conclusions
Humans and mice raise antibody responses to enteroviral proteases 2A and 3C after enterovirus
infection and this response can be used to dierentiate between acute on-going infections and those
that occurred previously. After an initial CVB infection in mice, the antibody response towards the
proteases is short-lived, peaking at around 7dpi and fading o by 21 dpi. For the human samples,
based on our limited dataset of IgM positive acute infections and IgM negative healthy controls, the
protease antibody IgG response is a good metric for a recent or on-going infection. Therefore, the use
of protease antibody responses in diagnosing enterovirus infections shows promise, although a larger
set of samples, preferably from dierent populations, should be screened to verify the results of the
current study and to establish criteria for diagnostic assay.
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Appendix A
Appendix A.1 Mouse Infection and Sample Collection
Approximately eight-week-old mice were infected by intraperitoneal 200 L injection with
Coxsackie B 3 viruses (CVB3) or mock-infected with phosphate buered saline (PBS). Sera from mock
(PBS, n = 4), or CVB3 strain Nancy (105 PFU, n = 7) infected mice were collected at dierent time points
before and after infection. Animals were also infected with CVB3 at a dose of 102 PFU for harvesting
organs. Animal health was carefully monitored. The mice that were infected for organ harvesting
were sacrificed at 3 dpi, whereas the other animals were monitored until 21 dpi, unless euthanized due
to reaching humane end-point criteria.
Appendix A.2 Histology
Mice pancreata were recovered from animals sacrificed on 3 dpi, fixed for 24 h in 4%
formaldehyde and embedded in paran. The formalin fixed tissues were cut into 5 m sections
and immunohistochemical staining was performed with antibodies targeting 3C or VP1 as described
earlier [21]. In brief, tissue sections were stained with a biotinylated primary antibodies to VP1 (Dako,
clone 5-D8/1, biotinylated by Capra Science, Sweden, and here denoted VP1-bio) or an antibody
to 3C [21]. Detection of 3C was performed using a biotinylated goat anti-rat IgG antibody (Vector
Laboratories, USA). Finally, biotin was detected using the Vectastain Elite ABC HRP kit (Peroxidase,
Vector Laboratories, USA). A dilution of 1:100 was used with the biotinylated VP1 antibody to avoid
possible cross-reactivity previously reported with the Dako antibody [30]. Control staining was
performed by omitting the primary antibodies in order to further ensure specificity.
Appendix A.3 Optimization of Protease-ELISA
The optimal conditions for coating ELISA-plates were screened for the dierent antigens with
regards to the coating buer and antigen concentrations. Also, dierent dilutions of pooled sera from
the infected mice and a human immunoglobulin concentrate Nanogam® were tested to establish a
proper analysis concentration range for the sera included in the experiments.
A dilution series from 80 g/mL to 0.625 g/mL with 1:2 dilution steps was prepared for 2A, 3C,
and 10 g/mL to 0.5 g/mL for VP1 proteins and inactivated viruses in phosphate buered saline (PBS)
or 50 mM carbonate buer pH 9.6. Dierent secondary anti-mouse-IgG antibodies were tested until
one that did not directly bind to the enterovirus antigens were found.
Nanogam has approximately 10 times the concentration of IgG in normal serum and we found
that a dilution of 1:10,000 was suitable as a positive control. For mice, we used 1:1000 dilution of pooled
infected mice end-point serum (collected at humane end-point or at 21 dpi) as a positive control.
The acute human samples (IgM positive) were first assayed with 1:250, 1:1000, and 1:4000 dilutions
and compared to a smaller set of six control sera. Based on this data set, the dilution 1:1000 was chosen
as the dierences between the groups were greatest with that dilution. Later, when more control serum
samples and the DIPP-samples were obtained all the human samples were assayed at 1:1000 dilution.
This way the majority of human sample data was assayed twice with matching results.
Interassay variability percentages (IAV) were calculated with R using the following formula
within test series:
IAV = (
s

)  100 (A1)
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where s = standard deviation and  = mean. IAV values were calculated for each antigen positive and
negative controls.
The assay was further optimized before running the bulk of human samples. While optimizing
the protease ELISA for humans using Nanogam®, there was still greater background for the proteases
than for the structural proteins. As a result, dierent primary antibody incubation temperatures and
times were tested. 1 h +37 C, 2 h RT or o/n at +4 C were tested and we noticed that with RT or higher
temperature, there was significantly more background also in the serumless control wells. As a result,
we conducted the human tests performing the serum incubation at +4 C o/n.
Appendix A.4 Preparation of ELISA Antigens
The VP1 antigen (CVB3, strain Nancy) were prepared as described in [20]. Briefly, attL-flanked
His-tagged VP1 protein coding synthetic genes were ordered from Life technologies and Gateway
cloned into pBVboostFGII-vector [31,32] for antigen production. After sequence verification, the VP1
containing plasmids were transferred to E. coli BL21 DE3 Star cells, the proteins were expressed by
inducing the cells with Isopropyl beta-D-1-thiogalactopyranoside and the produced recombinant
proteins were purified from clarified bacterial cell lysate using immobilized metal anion chromatography
(Ni-NTA IMAC). The purified VP1 proteins were dialyzed into pH 7.5 50 mM Tris, 150 mM NaCl
Tris-buered saline (TBS) and stored at  70 C.
The production of recombinant proteases 3C and 2A was carried out as in [21] using E. coli strain
BL21-AI as expression host. Purification was performed with ÄktaP-100 equipment using IMAC
Histrap FF crude columns (GE Healthcare Bio-Science AB). The proteases were dialyzed into 25 mM
HEPES buer (140 mM NaCl, 2.5 mM EDTA, 2 mM TCEP, 2% trehalose, pH 8.0), lyophilized and stored
at  20 centigrade.
The adenovirus and parainfluenzavirus antigens were obtained from Heikki Hyöty’s laboratory.
These included two parainfluenza antigens (type 1 and type 3, Serion Immunologics BA1216VS, and
BA1263FEC respectively) and one Adenovirus antigen (type 2 Hexon, Serion Immunologics, BA128VS).
Appendix A.5 Virus Culturing
Appendix A.5.1 Culturing Viruses for Infecting Mice
The Coxsackievirus B3 strain “Nancy” was grown in HeLa cells for 24–48 h and then cells were
freeze-thawed three times. The culture media was collected, centrifuged at 4000 rpm for 5 min and the
supernatant was removed and stored at  80 C. Virus titers were determined by a standard plaque
assay technique using HeLa cells.
Appendix A.5.2 Culturing Viruses for ELISA
CVB3 ATCC strain Nancy was grown in green monkey kidney cells (Vero) as described
previously [6,22]. Viruses were recovered from the clarified Vero-cell culture supernatants by 30%
sucrose cushion pelleting (175,000 g, 16 h at 4 C) and were further purified by gelatin anity
chromatography and pelleting through discontinuous 30%/50% sucrose cushion (285,000 g, 16 h at
4 C). Purified viruses were characterized as described previously [22,33] and the heat inactivation of
the purified virus was carried out by incubating the virus at +58 C for 30 min.
Appendix A.6 Protease ELISA for the Infected Mice
The antibody response towards CVB3 proteases and structural proteins (VP1 and heat inactivated
CVB3; Nancy) were analyzed through indirect ELISA with dilutions ranging from 1:250 to 1:256,000.
Assay conditions were optimized for the dierent antigens using pooled serum samples from CVB3
infected mice and by testing dierent secondary antibodies.
Nunc Maxisorp plate wells were coated with antigens (in a volume of 50 L/well: A total of
1 g/well of 2A, or 3C in PBS pH 7 or 250 ng/well of VP1 or heat inactivated CVB3 virus 50 ng/well in
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50 mM carbonate buer pH 9.6) overnight (o/n) at room temperature (RT). Wells were washed and
blocked for 30 min in 250 L/well of 0.1% BSA in PBS at +37 C. Next, the serum sample dilutions
ranging from 1:250 to 1:64,000 were incubated first at +37 C for 1 h and then overnight at +4 C.
Subsequently the wells were washed and incubated with 1:1000 dilution of goat anti mouse IgG
(Histofine) secondary antibody at +37 C for 1h. After washing the color reaction was developed by
adding 100 L/well of Sigma OPD substrate solution followed by 30 min incubation at 37 C before the
reaction was stopped with 100 L/well 0.5 M H2SO4. Absorbances were read at 490 nm with Victor
Wallac plate reader (Perkin Elmer, Turku, Finland).
Similar protease antibody signal fold changes were seen in serum sample diluted from 1:250
to 1:16,000 in CVB3 infected mice, and we therefore decided to show results from the 1:1000 serum
dilutions. Stronger responses to VP1 and inactivated virus were detected than those for the proteases
and as such these fold changes were calculated using the 1:64,000 dilutions.
The mouse samples were assayed twice and on the second assay round, the same range of sample
dilutions was assayed with the proteases, but VP1 and whole virus responses were assayed from
1:32,000 to 1:1,000,000. Coating of the proteases was verified using the protease-specific monoclonal
antibodies generated earlier [21].
Pooled endpoint sera from CVB1 and CVB3 infected mice at time of euthanasia (upon reaching
the humane end point) or at 21 dpi at 1:1000 dilution was used as positive control on each plate and
wells without serum were used as negative controls (Table S2 for interassay variabilities).
Appendix A.7 Protease ELISA for Human Samples
Optimization was performed using Nanogam®, a pooled human IgG product used for treating
agammaglobulinaemia. As a negative control for initial screening with Nanogam®, 20 serum samples
from 6-month-old children from the DIPP-study were screened for 2A, 3C, and VP1 antibodies. The idea
was that children of this age would not have maternal antibodies left and most likely would still
not have developed their own antibodies against enteroviruses. Additionally, sera from 22 patients
diagnosed to have an acute enterovirus infection according to IgM assay were assayed against sera
from 20 IgM negative healthy individuals with similar age distribution to test if the protease ELISA
can recognize acute infection.
Human samples were assayed as duplicates at 1:1000 dilutions. The protocol was the same as for
the mouse samples, with the exception of added parainfluenza and adenovirus antigens and the positive
control serum being 1:10,000 dilution for Nanogam® and the primary antibody incubation lasting
overnight at +4 C. The two parainfluenzavirus antigens were coated in the same wells with equimolar
amounts, 25 ng of each in a total volume of 50 L/well and the adenovirus antigen was coated with
50 ng in a volume of 50 L/well. Both were diluted in PBS. Consult Table S3 for interassay variabilities.
Appendix A.8 Capture IgM-ELISA for Human Samples
Enterovirus IgM antibodies were analyzed by a standard method used in clinical virus diagnostic
laboratory in the Turku University Hospital, as described by [23]. Briefly, the polystyrene wells were
coated with anti-human IgM antibodies (0.25 g/well). Serum samples were added as duplicates in a
dilution of 1:100. After 90 min incubation the wells were washed three times with PBS and a mixture of
ECHO11, CAV16 and CVB3 antigens, representing Enterovirus A and B species, were added. After 1-h
incubation, the wells were washed and incubated with a mixture of rabbit antibodies against ECHO11,
CVA16, and CVB3 for one hour. Finally, the color reaction was developed with OPD substrate and
stopped with 0.5 M H2SO4. Absorbance values over three times of the absorbance value of a negative
control serum were considered positive.
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